PuSH - Publication Server of Helmholtz Zentrum München

Weigand, L.U.* ; Liang, X.* ; Schmied, S.* ; Mall, S.* ; Klar, R.* ; Stötzer, O.J.* ; Salat, C.* ; Götze, K.* ; Mautner, J. ; Peschel, C.* ; Krackhardt, A.M.

Isolation of human MHC class II-restricted T cell receptors from the autologous T-cell repertoire with potent anti-leukaemic reactivity.

Immunology 137, 226-238 (2012)
Publ. Version/Full Text Volltext DOI PMC
Closed
Open Access Green as soon as Postprint is submitted to ZB.
Adoptive transfer of T cells genetically modified with tumour-specific T-cell receptors (TCR) is a promising novel approach in the treatment of cancer. We have previously isolated an allorestricted MHC class I-restricted TCR with specificity for Formin-like protein 1 (FMNL1) with potent activity against chronic lymphocytic leukaemia cells. CD4(+) T cells have been described to be highly important for tumour elimination although TCR derived from CD4(+) T cells with anti-tumour reactivity have been only rarely described. In this study we aimed to isolate MHC class-II-restricted CD4(+) T cells and TCR with specificity for leukaemia antigens. We used professional antigen-presenting cells pulsed with the leukaemia-associated and tumour-associated antigen FMNL1 for stimulation of autologous T cells in vitro. We isolated two CD4(+) HLA-DR-restricted T-cell clones and T-cell-derived TCR with so far unknown specificity but high reactivity against lymphoma cells and native malignant cells derived from HLA-matched patients with diverse leukaemias. Moreover, characterization of the TCR after TCR gene transfer revealed that specific characteristics of isolated TCR as reactivity in response to Toll-like receptors were transferable on effector cells. Our results have a major impact on the development of novel immunotherapies. They demonstrate that TCR with potent HLA-DR-restricted anti-leukaemic reactivity against so far undefined self-restricted antigens can be isolated from the healthy autorestricted CD4(+) T-cell repertoire and these TCR are highly interesting candidate tools for novel immunotherapies.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
3.321
0.983
10
9
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Scientific Article
Keywords leukaemia; lymphoma; myeloma; MHC; HLA; T-cell receptor (TCR); therapy; immunotherapy; toll receptors; Toll-like receptors; ENHANCED ANTITUMOR-ACTIVITY; HUMAN-LYMPHOCYTES; TUMOR-ANTIGEN; PEPTIDE; TCR; MELANOMA; IMMUNITY; TRANSPLANTATION; AUTOIMMUNITY; VACCINATION
Language english
Publication Year 2012
HGF-reported in Year 2012
ISSN (print) / ISBN 0019-2805
e-ISSN 1365-2567
Journal Immunology
Quellenangaben Volume: 137, Issue: 3, Pages: 226-238 Article Number: , Supplement: ,
Publisher Wiley
Reviewing status Peer reviewed
POF-Topic(s) 30504 - Mechanisms of Genetic and Environmental Influences on Health and Disease
Research field(s) Immune Response and Infection
PSP Element(s) G-520100-001
G-520900-001
PubMed ID 23025755
Erfassungsdatum 2012-11-14